Clinical Efficacy Of Hydrogen Molecule In Patients With Type 2 Diabetes Mellitus

Objective:To observe the clinical efficacy of hydrogen molecule（H₂）in patients with type 2diabetes mellitus（T2DM）,to verify the potential of hydrogen molecule in the treatment of T2DM,and to analyze the possible mechanism of its role,so as to provide evidence-based medical evidence for hydrogen molecule therapy of T2DM.Methods:Eighty patients with T2DM were treated in the Department of Endocrinology,a tertiary hospital of Jilin University from December 2021 to October 2022.The patients were randomly divided into observation group（n=40）and control group（n=40）.Patients in both groups were treated with Dapagliflozin（Astra Zeneca Pharmaceutical Limited Company,Anda Sugar,J20170040,10mg/tablets）once a day for hypoglycemic treatment,and were given basic education such as diabetes diet,exercise control,smoking cessation and alcohol restriction.On this basis,the observation group drank 2000ml of hydrogen-rich water daily,combined with inhaled hydrogen 2h/d,and the control group replaced hydrogen-rich water with pure water.Do not inhale hydrogen.The course of treatment in both groups was 12 weeks.Finally,37patients were enrolled in the observation group and 38 patients in the control group.Before treatment and 12 weeks after treatment,the following indexes were monitored and recorded:body weight,body mass index（BMI）,systolic blood pressure（SBP）,diastolic blood pressure（DBP）,fasting blood glucose（FPG）,2-hour postprandial blood glucose（2h PG）,glycosylated hemoglobin（Hb A1c）,triglyceride（TG）,total cholesterol（TC）,low density lipoprotein cholesterol（LDL-C）,high density lipoprotein cholesterol（HDL-C）,uric acid（UA）,homeostisis modle assessment-insulin resistance index（HOMA-IR）homeostisis modle assessmentβ-cell function index（HOMA-β）.Observe and record the incidence of hypoglycemia,genitourinary system infection and other adverse reactions in the two groups,and give them correct treatment.Results:（1）A total of 80 patients who met the inclusion and exclusion criteria were included in this study,and 5 patients dropped out during the follow-up.The number of patients who completed the follow-up was 75,including 37 patients in the observation group and 38 patients in the control group.There was no significant difference in baseline data between the two groups（P>0.05）.（2）After 12 weeks of treatment,the body weight and BMI of the observation group and the control group were lower than the baseline level,but there was no significant difference between the two groups（P>0.05）.（3）After 12 weeks of treatment,the SBP and DBP of the observation group and the control group were lower than the baseline level（P<0.05）,but there was no significant difference between the two groups（P>0.05）.（4）After 12 weeks of treatment,the FPG,2h PG and Hb A1c of the observation group and the control group were lower than the baseline level（P<0.05）.The FPG and Hb A1c levels of the observation group were significantly lower than those of the control group（P<0.01,P<0.05）,and there was no significant difference in 2h PG between the two groups（P>0.05）.（5）After 12 weeks of treatment,the TC and TG levels of the observation group and the control group were lower than the baseline levels（P<0.05）,and the TC and TG levels of the observation group were significantly lower than those of the control group（P<0.05）.There was no significant difference in LDL-C and HDL-C between the two groups before and after treatment（P>0.05）.（6）After 12 weeks of treatment,the UA levels of the observation group and the control group were lower than the baseline level（P<0.05）,and the UA level of the observation group was significantly lower than that of the control group（P<0.05）.（7）After 12 weeks of treatment,HOMA-IR in the observation group and the control group was lower than the baseline level（P<0.05）,and HOMA-βwas higher than the baseline level（P<0.05）.HOMA-IR in the observation group was significantly lower than that in the control group（P<0.05）.HOMA-βin the observation group was significantly higher than that in the control group（P<0.05）.（8）There was no significant difference in the incidence of hypoglycemia between the observation group and the control group（P>0.05）,no significant difference in the incidence of genitourinary system infection（P>0.05）,and no other adverse reactions were observed.Conclusion:（1）Hydrogen molecule can improve blood glucose and lipid levels,reduce uric acid,alleviate IR and improve isletβcell function in T2DM patients.（2）Molecular hydrogen has a good safety profile and,unlike drugs but similar to exercise,may require daily and long-term intake for optimal clinical effects because H₂ingestion is simple and safe.As a habitual auxiliary health therapy,it can prevent,maintain and treat T2DM in the early stage.